Trial Profile
A study evaluating safety of Ranibizumab treatment for neovascular age related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 16 May 2017 New trial record